Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12617001342303p
Ethics application status
Submitted, not yet approved
Date submitted
12/09/2017
Date registered
22/09/2017
Date last updated
22/09/2017
Type of registration
Prospectively registered
Titles & IDs
Public title
Testing low risk penicillin allergic hospital patients with a single dose of oral amoxicillin
Query!
Scientific title
Safety of direct oral amoxicillin challenge study of penicillin allergic general medical hospital inpatients.
Query!
Secondary ID [1]
292867
0
nil known
Query!
Universal Trial Number (UTN)
NA
Query!
Trial acronym
NA
Query!
Linked study record
NA
Query!
Health condition
Health condition(s) or problem(s) studied:
penicillin allergy
304713
0
Query!
Condition category
Condition code
Inflammatory and Immune System
304021
304021
0
0
Query!
Allergies
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Carefully selected patients with penicillin allergy who are deemed at low risk of immediate hypersensitivity reaction will be given a test oral dose of amoxicillin 250mg capsule and monitored for reaction. This is a safety and feasibility study.
Query!
Intervention code [1]
299110
0
Diagnosis / Prognosis
Query!
Comparator / control treatment
This is an uncontrolled study
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
303355
0
Safety of direct oral amoxicillin challenge of low risk hospital inpatients - patients will be clinically monitored for one hour after their dose of amoxicillin. Clinical outcomes which will be monitored for include rash, change in blood pressure (measured with sphygmomanometer) or heart rate (pulse oximeter), breathing difficulties or wheeze, facial swelling, and any other symptoms patient's report.
Query!
Assessment method [1]
303355
0
Query!
Timepoint [1]
303355
0
Patient's will only be monitored for an hour after the dose.
Query!
Secondary outcome [1]
338732
0
feasibility of penicillin allergy testing in the acute hospital inpatient setting - this will be monitored in terms of ease of recruiting patients, and administering test amoxicillin doses during a patient's general medical admission, without obstructing their normal care. The outcome will be assessed by means of interviews with medical staff.
Query!
Assessment method [1]
338732
0
Query!
Timepoint [1]
338732
0
At end of study - ideally after 100 patients recruited
Query!
Eligibility
Key inclusion criteria
Patient's admitted to the general medical service of Christchurch Hospital with recorded penicillin allergy
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Previous allergic reaction within 1 hour of administration of penicillin (urticaria, angioedema, bronchospasm, anaphylaxis).
Previous severe cutaneous drug reaction (blistering) following penicillin
Delayed reaction with mucosal, systemic or organ involvement following penicillin
End of life/actively dying
Haemoydnamically unstable
Physiological frailty (physician discretion)
Serum sickness reaction
Pregnant
Query!
Study design
Purpose of the study
Diagnosis
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
NA
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
NA
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Safety
Query!
Statistical methods / analysis
As this is an intitial safety/feasibility study, we are aiming to recruit roughly 100 patients, We will then expand the study across our institution.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
6/11/2017
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
5/03/2018
Query!
Actual
Query!
Date of last data collection
Anticipated
9/03/2018
Query!
Actual
Query!
Sample size
Target
100
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
9202
0
New Zealand
Query!
State/province [1]
9202
0
Canterbury
Query!
Funding & Sponsors
Funding source category [1]
297496
0
Hospital
Query!
Name [1]
297496
0
Christchurch Hospital
Query!
Address [1]
297496
0
Christchurch Hospital,
2 Riccarton Ave, Christchurch Central, Christchurch 8011
Query!
Country [1]
297496
0
New Zealand
Query!
Primary sponsor type
Individual
Query!
Name
Heather Isenman
Query!
Address
Department of Infectious Diseases,
Christchurch Hospital,
2 Riccarton Avenue, Christchurch Central, 8011
Query!
Country
New Zealand
Query!
Secondary sponsor category [1]
296501
0
Individual
Query!
Name [1]
296501
0
Alan Pithie
Query!
Address [1]
296501
0
Department of Infectious Diseases,
Christchurch Hospital,
2 Riccarton Avenue, Christchurch Central, 8011
Query!
Country [1]
296501
0
New Zealand
Query!
Ethics approval
Ethics application status
Submitted, not yet approved
Query!
Ethics committee name [1]
298596
0
Health and Disability Ethics Committe New Zealand
Query!
Ethics committee address [1]
298596
0
Ministry of Health Health and Disability Ethics Committees PO Box 5013 Wellington 6140
Query!
Ethics committee country [1]
298596
0
New Zealand
Query!
Date submitted for ethics approval [1]
298596
0
12/09/2017
Query!
Approval date [1]
298596
0
Query!
Ethics approval number [1]
298596
0
Query!
Summary
Brief summary
Penicillin allergy is reported by between 10 and 20% of hospital inpatients, However, fewer than 10% of these patients have allergy confirmed on formal testing. Being labelled as penicillin allergic carries a substantial burden. There is increased length of stay, cost, and adverse outcomes associated with penicillin allergy, a need for alternative antimicrobial agents, and potential for treatment failure and readmission. Accordingly, the recent Infectious Diseases Society of America (IDSA) antimicrobial stewardship guidelines recommend reviewing patient’s antibiotic allergy status as an integral stewardship intervention. An immediate hypersensitivity or IgE mediated reaction is normally excluded by skin testing, followed by an oral challenge, as recommended by the Australasian Society of Clinical Immunology and Allergy (ASCIA). Skin testing requires: (i) specific reagents, some of which are in short supply, and (ii) expertise and manpower to execute, and is thus not always feasible in a busy hospital setting. Skin tests are positive in between 0.8% and 4% and of patients. Of patients with a negative skin test given an oral challenge, only 0.8% to 1.5% of patients experience reactions, typically cutaneous rather than anaphylactic. A recent study challenged 328 low risk penicillin allergic outpatients with a single dose of oral amoxicillin, without prior skin testing. There were only 5 (1.5%) cutaneous reactions, with no episodes of anaphylaxis. There have been no studies assessing direct oral challenge of hospital inpatients, but successful approaches utilising skin testing to determine allergy status in hospital inpatients. Based on this data and the low rate of 'true' allergy in the form of immediate hypersensitivity amongst reportedly penicillin allergic patients, we feel that it should be feasible to administer an oral challenge to carefully selected low risk hospital inpatients. The ASCIA guidelines suggest that in cases where the clinical history does not suggest an IgE mediated allergy, skin testing is not required, and a direct oral challenge may be given. This will enable a more proactive, real time stewardship intervention than skin testing, which is often delayed to the outpatient setting.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
77602
0
Dr Heather Isenman
Query!
Address
77602
0
Department of Infectious Diseases, 2 Riccarton Ave, Christchurch Central, Christchurch 8011
Query!
Country
77602
0
New Zealand
Query!
Phone
77602
0
+64 3 364 0640
Query!
Fax
77602
0
Query!
Email
77602
0
[email protected]
Query!
Contact person for public queries
Name
77603
0
Heather Isenman
Query!
Address
77603
0
Department of Infectious Diseases, 2 Riccarton Ave, Christchurch Central, Christchurch 8011
Query!
Country
77603
0
New Zealand
Query!
Phone
77603
0
+64 3 364 0640
Query!
Fax
77603
0
Query!
Email
77603
0
[email protected]
Query!
Contact person for scientific queries
Name
77604
0
Heather Isenman
Query!
Address
77604
0
Department of Infectious Diseases, 2 Riccarton Ave, Christchurch Central, Christchurch 8011
Query!
Country
77604
0
New Zealand
Query!
Phone
77604
0
+64 3 364 0640
Query!
Fax
77604
0
Query!
Email
77604
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF